Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1399-1408

  Xu, Maolei ^a   Xing, Yun ^a   Zhou, Ling ^a   Yang, Xue ^a   Yao, Wenjun ^a   Xiao, Wen ^a   Ge, Chiyu ^a   Ma, Yanjun ^a   Yang, Jie ^a   Wu, Jie ^a   Cao, Rongyue ^a   Li, Taiming ^a   Liu, Jingjing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; B16F10 melanoma; Human umbilical vein endothelial cells; OK432

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELL OK 432 VACCINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELL VACCINE; IMMUNOGLOBULIN G ANTIBODY; OKT 432; PICIBANIL; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84878725548     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0616-8     Document Type: Article

References (31)

1. Chen IJ, Yen CF, Lin KJ, Lee CL, Soong YK, Lai CH, Lin CT. Vaccination with OK-432 followed by TC-1 tumor lysate leads to significant antitumor effects. Reprod Sci. 2011;18(7):687-94. doi: 10.1177/1933719110396230.
2. Huang L, Ohno T. Protective antitumor immunity induced by fixed tumor cells in combination with adjuvant in a murine hepatoma model. Cancer Lett. 2003;202(2):153-9.
3. Novakovic S, Stegel V, Kopitar A, Ihan A, Novakovic BJ. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine. 2007;25(49):8241-56. doi: 10.1016/j.vaccine.2007.09.067.
4. Suckow MA, Rosen ED, Wolter WR, Sailes V, Jeffrey R, Tenniswood M. Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine. Cancer Immunol Immunother. 2007;56(8):1275-83. doi: 10.1007/s00262-006-0278-8.
5. Yin W, He Q, Hu Z, Chen Z, Qifeng M, Zhichun S, Zhihui Q, Xiaoxia N, Li J, Gao J. A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer. Vaccine. 2010;28(31):4937-44.
6. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY, Lee JH, Lee SK, Lee SN, Jung SS, Han JY, Kim H, Lee JY, Yoo NJ. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 2001;61(13):4942-6.
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-6. doi: 10.1056/NEJM197111182852108.
8. Liao F, Doody JF, Overholser J, Finnerty B, Bassi R, Wu Y, Dejana E, Kussie P, Bohlen P, Hicklin DJ. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res. 2002;62(9):2567-75.
9. Stopeck AT, Unger JM, Rimsza LM, Leblanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood. 2012. doi: 10.1182/blood-2012-04-423079.
10. Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A, Morse MA, Uronis HE, Marcom PK, Zafar SY, Haley ST, Hurwitz HI. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer chemotherapy and pharmacology. 2012. doi: 10.1007/s00280-012-1911-1.
11. Wang R, Qin S, Chen Y, Li Y, Chen C, Wang Z, Zheng R, Wu Q. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer. Oncology reports. 2012;28(2):439-45. doi: 10.3892/or.2012.1828.
12. Xu HM, Yin R, Chen L, Siraj S, Huang X, Wang M, Fang H, Wang Y. An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo. Bioconjugate chemistry. 2008;19(10):1980-6. doi: 10.1021/bc800132p.
13. Okaji Y, Tsuno NH, Saito S, Yoneyama S, Tanaka M, Nagawa H, Takahashi K. Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy. Eur J Surg Oncol. 2006;32(4):363-70. doi: 10.1016/j.ejso.2006.01. 016.
14. Chen XY, Zhang W, Wu S, Bi F, Su YJ, Tan XY, Liu JN, Zhang J. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin Cancer Res. 2006;12(19):5834-40. doi: 10.1158/1078-0432.ccr-06-1105.
15. Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, Yazawa K, Asakage M, Hori N, Watanabe T, Shibata Y, Takahashi K, Nagawa H. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci. 2004;95(1):85-90.
16. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, Xiao F, He QM, Shu JM, Xie XJ, Mao YQ, Lei S, Luo F, Zhou LQ, Liu CE, Zhou H, Jiang Y, Peng F, Yuan LP, Li Q, Wu Y, Liu JY. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nature Med. 2000;6(10):1160-6. doi: 10.1038/80506.
17. Okaji Y, Tsuno NH, Tanaka M, Yoneyama S, Matsuhashi M, Kitayama J, Saito S, Nagura Y, Tsuchiya T, Yamada J, Tanaka J, Yoshikawa N, Nishikawa T, Shuno Y, Todo T, Saito N, Takahashi K, Nagawa H. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer. 2008;44(3):383-90. doi: 10.1016/j.ejca.2007.10.018.
18. Abe J, Wakimoto H, Aoyagi M, Hirakawa K, Hamada H. Cytokine-gene-modified tumor vaccination intensified by a streptococcal preparation OK-432. Cancer immunology, immunotherapy: CII. 1995;41(2):82-6.
19. Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized phase III trial. Cancer. 1998;83(10):2054-9.
20. Lee YC, Luh SP, Wu RM, Lee CJ. Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection. Cancer Immunol Immunother. 1994;39(4):269-74.
21. Okazaki T, Iwatani S, Yanai T, Kobayashi H, Kato Y, Marusasa T, Lane GJ, Yamataka A. Treatment of lymphangioma in children: our experience of 128 cases. J Pediatr Surg. 2007;42(2):386-9. doi: 10.1016/j.jpedsurg.2006.10.012.
22. Fujimoto T, Duda RB, Szilvasi A, Chen X, Mai M, O'Donnell MA. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol. 1997;158(12):5619-26.
23. Kuroki H, Morisaki T, Matsumoto K, Onishi H, Baba E, Tanaka M, Katano M. Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 2003;52(9):561-8. doi: 10.1007/s00262-003-0394-7.
24. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 2003;63(14):4112-8.
25. Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 2004;64(15):5461-70. doi: 10.1158/0008-5472.can-03-4005.
26. Yang J, Zhang Y, Wang H, Gao Z, Wang Z, Liu B, Zhang X, Du M, Huang X, Xu M, Wu J, Li T, Liu J, Cao R. Vaccination with the repeat beta-hCG C-terminal peptide carried by heat shock protein-65 (HSP65) for inducing antitumor effects. Tumour Biol. 2012. doi: 10.1007/s13277-012-0437-9.
27. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer. 1996;32A(14):2451-60.
28. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4-6. doi: 10.1093/jnci/82.1.4.
29. Weidner N. Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol. 2000;31(4):403-5. doi: 10.1053/hp.2000.6724.
30. Huiyong Z, Yong L, Didier M, Yu Z, Jing F, Rongyue C, Jingjing L. Enhanced inhibition of murine prostatic carcinoma growth by immunization with or administration of viable human umbilical vein endothelial cells and CRM197. Braz J Med Biol Res. 2011;44(2):140-8.
31. Yoneyama S, Okaji Y, Tsuno NH, Kawai K, Yamashita H, Tsuchiya T, Yamada J, Sunami E, Osada T, Kitayama J, Takahashi K, Nagawa H. A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. Eur J Surg Oncol. 2007;33(10):1191-8. doi: 10.1016/j.ejso.2007.01. 013.